Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing 06

YO15 - Nasopharyngeal carcinoma in pregnancy: A Case Report


03 Dec 2022


Poster viewing 06


Cancer and Pregnancy;  Multi-Disciplinary and Multi-Professional Cancer Care

Tumour Site

Head and Neck Cancers


Mary Antonette Ong


M.A.G. Ong

Author affiliations

  • Internal Medicine Department, Iloilo Mission Hospital, 5000 - Iloilo City/PH


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract YO15

Case summary

Nasopharyngeal carcinoma in pregnancy: A Case Report


Nasopharyngeal carcinoma (NPC) in pregnancy presents a dilemma in managing the patient with much consideration to both mother and the unborn child.

Aims: To present the treatment outcome of nasopharyngeal carcinoma in pregnancy. Methods/design: Case report.

Results: This is a case of a 33-year old female who presented with a gradually enlarging bilateral neck masses during her second trimester of pregnancy. Her neck CT Scan showed a nasopharyngeal mass which was more prominent at the right measuring 3.3 x 5.3 x 3.0 cm. There were inhomogenously enhancing lobulated densities in the lateral cervical areas with the largest measuring 11.6 x 5.8 x 7.0 cm. Inhomogenously enhancing densities were seen in the supraclavicular, posterior and anterior cervical and submandibular areas with the largest seen at the right supraclavicular area measuring 1.8 x 2.5 x 2.1 cm. Punch biopsy of the nasopharyngeal mass revealed it to be morphologically consistent with nasopharyngeal carcinoma, non keratinizing, differentiated type (T3N3M0). Metastatic work up was unremarkable. She consented to begin her treatment with Gemcitabine and Cisplatin every 21 days as induction chemotherapy. Since the neck masses continued to rapidly increase in size after three cycles of chemotherapy, she was shifted to Paclitaxel and Carboplatin. At 26 weeks of gestation, she delivered a male infant weighing 970 grams with APGAR scores of 8 and 8 at 1 and 5 minutes, respectively, via normal vaginal spontaneous delivery with complete breech extraction. She has completed 6 cycles of chemotherapy and 70 Gy in 35 fractions of intensity modulated radiation therapy. The infant showed no anatomical and organ malformations. The patient showed an almost complete response after six cycles of chemotherapy.

Conclusion: Systemic chemotherapy in a pregnant NPC patient can be administered initially as a means of a delaying measure to reach a certain period of gestation where it is safer to deliver the baby. Radiation therapy can follow after the delivery to spare the unborn child from the hazards of radiation. Guided and shared decision making between the patient, family, and her physicians is vital in directing the management of NPC in pregnancy.

Clinical trial identification

Editorial acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.